Sulfatrim

Quick links to important sections

Sulfatrim

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulfatrim

Quick Facts: Sulfatrim

Property Description
Active ingredients Sulfamethoxazole, Trimethoprim
Form Tablet, Oral Suspension, Solution for Injection
Pharmacological class Antibacterial agent, Fixed-Dose Combination
General purpose Management of systemic bacterial infections
Origin Synthetic

Sulfatrim is the brand name for a synthetic, prescription-only antibacterial agent officially known as Co-trimoxazole (INN). This combination is widely used in medicine and is recognized as an effective antimicrobial agent for managing conditions associated with the presence of susceptible bacteria in the body. The combination itself is one of the most clinically recognized fixed-dose combination (FDC) products available globally.

What Type of Medicine is Co-trimoxazole?

Co-trimoxazole belongs to the high-level class of antibacterial agents and is an entirely synthetic entity. This combination is highly respected in clinical guidelines that confirm its reliability in fighting pathogens. The combination’s distinctive feature is the synergistic mechanism achieved by combining the sulfonamide Sulfamethoxazole with the antifolate Trimethoprim. This specific formulation is also widely known under other brands, such as Bactrim or Septra, all containing the same two active ingredients.

What is Sulfatrim’s Composition and Form?

Sulfatrim consists of the two core active ingredients, Sulfamethoxazole and Trimethoprim, prepared in a fixed ratio. The medicine is manufactured in several dosage forms, including the tablet for oral administration and the solution for injection for intravenous use, alongside an oral suspension. Co-trimoxazole is recognized as an essential medicine, confirming its proven efficacy and necessary role as a core therapeutic agent in global healthcare.

How Does Co-trimoxazole Generally Help the Body?

Co-trimoxazole generally helps the body by actively killing target microorganisms through a potent sequential blockade mechanism. This action is critical because the two components interrupt consecutive steps in the bacterial production of folic acid, which is essential for bacterial survival. By utilizing this dual attack, the resulting effect is strongly bactericidal, aiding the clearance of various bacterial diseases. Its consistent performance in this role is a key reason for its continued use in managing common systemic bacterial infections.

What side effects are possible with Sulfatrim?

Possible Side Effects and Safety Information

The safety profile of Co-trimoxazole (Sulfatrim) is comprehensively documented in regulatory sources, listing adverse reactions categorized by frequency and the body system affected. These classifications establish the risk framework for this antibacterial agent.

Officially documented side effects common to use are nausea, diarrhea, headache, and skin rash. A very common finding in regulatory documents is hyperkalaemia (high potassium levels in the blood), categorized as a Metabolism and Nutrition Disorder in the European Summary of Product Characteristics (SmPC). Other effects are grouped by affected System-Organ Class, including Gastrointestinal Disorders and Nervous System Disorders.

Serious adverse reactions, though rare, are officially listed. These include severe Hematologic Disorders, such as Agranulocytosis and Aplastic Anemia, and life-threatening Severe Cutaneous Adverse Reactions (SCARs) like Stevens-Johnson Syndrome (SJS). The highest risk for these severe skin reactions is typically during the first weeks of treatment.

Safety constraints and contraindications are clearly defined. The medication is officially contraindicated for use in infants less than 2 months of age and in patients with severe renal insufficiency or marked hepatic damage. The label also notes that older adults may be more susceptible to certain severe adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help: Sulfatrim (Sulfamethoxazole/Trimethoprim)

Overdosage of Sulfatrim can result in both acute and chronic toxicity, requiring immediate medical attention. Contact a physician or a poison control center immediately if overdose is known or suspected.

Documented Manifestations of Overdose

Type of Exposure Common Signs Severe/Life-Threatening Outcomes
Acute Toxicity Nausea, vomiting, headache, dizziness, and mental depression. Acute kidney injury, anuria (due to crystalluria), and severe hyperkalemia.
Chronic Toxicity Fever, weakness, fatigue. Bone marrow depression, leading to megaloblastic anemia, leukopenia, or thrombocytopenia.

Official Management and Treatment

Official regulatory documents emphasize immediate actions to manage overdose. Following withdrawal of the drug, immediate measures may include gastric lavage. Adequate fluid intake is recommended to maintain urine output and prevent crystalluria. For the trimethoprim component, the drug label specifies the use of leucovorin (folinic acid) to counteract the effects on hematopoiesis. Monitoring of serum electrolytes (specifically potassium) and complete blood counts is required during the observation period. Patients with impaired kidney function are recognized as being at increased risk for toxicity.

Therapeutic Uses of Sulfatrim

What Sulfatrim Treats: Main Uses and Benefits

The therapeutic purpose of Sulfatrim (trimethoprim/sulfamethoxazole) is commonly used in the symptomatic management of certain bacterial infections, which supports the body during periods of infectious symptom burden and eases the associated disruptive symptoms.

This combination is considered relevant for several key therapeutic areas, used in contexts involving conditions characterized by periods of heightened symptoms.

The medication is commonly used across conditions presenting with acute episodes such as bacterial urinary tract infections (UTIs), specific forms of acute exacerbations of chronic bronchitis, certain middle ear infections, and gastrointestinal infections including traveler's diarrhea. It is applied in addressing symptom clusters that may become intense or disruptive, specifically symptoms related to physical discomfort like pain, burning, and urgency.

“This medication generally provides support that helps ease the overall symptom burden, assisting with maintaining functional stability.”

Quick Fact: Relief for Acute Symptom Clusters

This medication is relevant for managing symptoms that interfere with daily comfort, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It contributes to easing the overall symptom load during periods of heightened systemic burden.

Eligibility and Restrictions for Use

Eligibility Scope

Classification Status Populations and Conditions Officially Defined
Approved Population Eligible Adults and pediatric patients two months of age and older.
Absolute Contraindication Prohibited Patients with known hypersensitivity to trimethoprim or sulfonamides.
Absolute Contraindication Prohibited Documented megaloblastic anemia due to folate deficiency.
Absolute Contraindication Prohibited Infants less than two months of age, pregnant patients, and nursing mothers.
Organ Function Restriction Prohibited Marked hepatic damage or severe renal insufficiency when renal status cannot be monitored (Creatinine Clearance < 15 mL/min).
Conditional Use Caution Elderly patients, patients with impaired renal function (CrCl 15 to 30 mL/min), and individuals with G6PD deficiency.

Resulting Eligibility Structure

The regulatory documents establish absolute prohibition for specific populations, including all infants under two months of age and patients with a history of severe allergies to either active component. Use is further prohibited for individuals with certain organ function limitations, such as marked liver damage, or metabolic conditions like acute porphyrias. Populations eligible for use, such as the elderly or those with chronic kidney impairment, are subject to regulatory warnings that require particular care and close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify certain combinations with Sulfatrim (Sulfamethoxazole/Trimethoprim) as prohibited or requiring specific constraints. Co-administration with Dofetilide is Contraindicated due to the risk of dangerously increased Dofetilide plasma concentrations, which can lead to severe cardiac adverse events. Concurrent use with Leucovorin for Pneumocystis jirovecii pneumonia treatment must be avoided.

Sulfatrim significantly modifies the exposure of other medicines through two main pharmacokinetic pathways. The Sulfamethoxazole component is an inhibitor of the CYP2C9 enzyme, resulting in increased plasma concentrations of drugs cleared by this pathway, such as Warfarin and Phenytoin. The Trimethoprim component acts as an inhibitor of CYP2C8 and the Organic Cation Transporter 2 (OCT2), affecting the levels of substances like Repaglinide and Metformin.

Pharmacodynamic and Population Constraints

Combining Sulfatrim with other agents that affect potassium balance, such as ACE Inhibitors, ARBs, or Potassium-sparing Diuretics, creates an additive risk of Hyperkalemia. The risk of elevated Digoxin blood levels is officially noted as being particularly significant when co-administered in elderly patients. The administration of Live Bacterial Vaccines must be temporally separated and occur only after the antibiotic course is complete, as stated in regulatory warnings.

Mechanism of Action

Dual Inhibition of Bacterial Folic Acid Synthesis

The core mechanism of Sulfatrim (Co-trimoxazole) is a specialized process known as sequential blockade, which targets the bacterial metabolic pathway for creating tetrahydrofolic acid ( FH4). The action occurs on two different enzymes: Sulfamethoxazole blocks DHPS (dihydropteroate synthase) and Trimethoprim blocks DHFR (dihydrofolate reductase) . By inhibiting these two consecutive steps, the drug halts the production of this essential cofactor, a foundational molecule needed for the microbe to build DNA and proteins.

Synergy Resulting in a Bactericidal Effect

The functional consequence of the drug arises from the synergy created by the dual inhibition; the combined effect of blocking both enzymes dramatically reduces FH4 to levels that are acutely terminal to the microbe. This coordinated action elevates the drug's physiological consequence from merely growth-inhibiting (bacteriostatic) to actively killing the pathogen (bactericidal). The mechanism targets the bacterial process and does not affect the host cell process, which relies on dietary folate rather than this targeted bacterial synthesis pathway.

Constraints on Mechanism Efficacy

The drug's effectiveness is constrained when bacteria evolve or acquire mechanisms to circumvent the blockade, such as developing resistance in the target enzymes ( DHPS or DHFR) or overproducing the natural substrate, PABA. Since Sulfamethoxazole acts through competitive inhibition, high substrate levels can functionally reduce the drug's binding, ultimately reducing the synergistic FH4 depletion.

Dosage and Administration Information

How to Use Sulfatrim (Co-trimoxazole)

The official usage of Sulfatrim is governed by precise instructions defining its route of administration, dose calculation, frequency, and preparation. The medicine is administered either orally, using tablets or oral suspension, or via slow intravenous (IV) infusion using the solution for injection. Oral forms, which include a Double Strength (DS) tablet (800 mg Sulfamethoxazole / 160 mg Trimethoprim), are typically taken twice daily (every 12 hours) for acute courses, though high-dose regimens for severe infections may require administration more frequently.

Administration and Dosing Principles

Usage Parameter Official Labeled Instruction
Oral Intake Condition May be taken without regard to meals; consumption of plenty of fluids is advised to minimize the risk of crystallization.
IV Preparation The concentrate must be diluted immediately before use (e.g., with 5% Dextrose in Water) and administered via slow infusion over 60 to 90 minutes; rapid injection is prohibited.
Duration of Use Varies by condition, ranging from short courses (e.g., five days) to extended courses (up to three weeks) for severe systemic infections.

Dose Adjustments

Official instructions mandate dose adjustments based on renal function. For adult patients with moderate kidney impairment (Creatinine Clearance 15-30 mL/min), the standard regimen must be halved. The medication is not approved for infants under two months of age. If a dose is missed, it should be taken as soon as remembered, unless the time for the next scheduled dose is near, in which case the patient should skip the missed dose and resume the usual schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Action Mechanism

Research has investigated whether the compound is associated with reductions in pain by acting as an antagonist at the A1 receptor. The proposed action is being investigated.


Pain Reduction Outcomes

Studies have explored outcomes across different types of chronic neuropathic pain. Phase II and III trials primarily focused on diabetic peripheral neuropathy and post-herpetic neuralgia.

  • Primary Endpoint: Pain severity assessment was conducted over a 12-week period, measured using the Numerical Rating Scale (NRS).
  • Time to Change: Some studies reported initial changes within 2 weeks of treatment start.
  • Dose Response: Trials examined varying oral doses, with 10 mg and 20 mg doses being the most frequently studied in Phase III.

Comparisons with Other Compounds

Phase III trials examined outcomes compared to the standard B treatment (a tricyclic antidepressant) and a placebo control.

  • The study design included a parallel-group, double-blind, randomized setting.
  • A pre-planned subgroup analysis investigated whether differences in outcomes existed for patients with refractory pain.

Impact on Associated Symptoms

Research investigated whether the combination was associated with patient sleep quality changes by examining its influence on the sleep-wake cycle. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). The A1 antagonist component was also explored for its potential association with anxiety symptoms in an ancillary study.


Pharmacokinetic Studies

Studies evaluated the extended-release formulation against the immediate-release formulation regarding absorption. The goal was to establish optimal dosing frequency and minimize peak-to-trough plasma concentration fluctuations.


Safety and Tolerability Profile

Trial participants included adult populations. Clinical trial exclusion criteria included participants with existing cardiac conditions and those with severe hepatic impairment.

Frequently Asked Questions (FAQ)

Common questions about Sulfatrim (FAQ)

Q: What are the main signs of an allergic reaction to Sulfatrim?

A: Official product information states that signs of a serious allergic reaction may include difficulty breathing, swelling of the face, tongue, or throat, or the appearance of hives and a skin rash. These types of severe reactions are officially noted as emergency situations.


Q: Can someone with a history of kidney problems take Sulfatrim?

A: Regulatory documents indicate that the medication is prohibited for individuals with severe kidney insufficiency. For those with lesser degrees of impaired kidney function, the drug can be used but often requires close monitoring and adjustment of the treatment regimen to align with official safety monitoring requirements.


Q: Is it true that Sulfatrim can increase sensitivity to the sun?

A: Yes, official safety information notes that the medication can increase the skin’s sensitivity to light from the sun or tanning equipment. This condition is called photosensitivity. The need for sun protection measures is often addressed by a healthcare professional.


Q: Is Sulfatrim safe for infants under two months old?

A: Regulatory documents state that Sulfatrim is absolutely contraindicated (prohibited) for infants under two months of age. This restriction exists because sulfonamides, one of the active ingredients, may be associated with a risk of kernicterus, a type of brain damage, in newborns.


Q: Why can Sulfatrim affect potassium levels in the blood?

A: The increase in potassium levels, known as hyperkalemia, is listed as a common finding in official documents. This component is described as potentially increasing potassium levels by affecting how the kidneys manage potassium elimination.


Q: Can taking Sulfatrim cause changes in mood or confusion?

A: Official drug labeling lists confusion as a potential sign of a serious adverse event or as a symptom related to electrolyte imbalances in the body. Other reported effects on the nervous system include headache and dizziness.


Q: Does Sulfatrim interact with common over-the-counter pain relievers?

A: Regulatory guidance on drug interactions indicates that Acetaminophen is generally considered acceptable for co-administration. However, official information indicates that caution is necessary with certain nonsteroidal anti-inflammatory drugs (NSAIDs), as these may reduce the body's ability to clear the trimethoprim component, potentially increasing its levels.


Q: What is the typical use of Sulfatrim for a urinary tract infection (UTI)?

A: According to official sources, the drug is a fixed-dose antibacterial agent used to manage various systemic bacterial infections. This includes common conditions like urinary tract infections (UTIs), as well as certain infections in the lungs and skin.


Q: Are there any long-term side effects associated with repeated courses of Sulfatrim?

A: Official safety information notes that using the medication for an extended or prolonged period, especially at high doses, is associated with specific risks. These risks include the potential for lowering the number of platelets in the blood, which are involved in the body's clotting process.


Q: Can Sulfatrim be safely used by people who have diabetes?

A: Regulatory sources advise that the drug should be used with caution by patients who have diabetes, as use may require specific oversight. Furthermore, Sulfatrim is known to interact with certain anti-diabetes medications, such as Repaglinide, which could lead to low blood sugar levels.


Q: Does Sulfatrim treat the common cold or flu?

A: Official product labeling classifies this medication as an antibacterial agent. It is designed to treat infections caused by susceptible bacteria and is therefore not indicated or effective for treating viral illnesses, such as the common cold or influenza (flu).


Q: Can Sulfatrim cause digestive issues like diarrhea even after finishing the prescription?

A: Official regulatory warnings note that some patients may experience a serious form of diarrhea associated with antibiotics. This can occur not only during treatment but also weeks or even months after the drug course has been completed.


Q: How long does Sulfatrim stay in the body after the last dose?

A: Pharmacokinetic information in official documents indicates that detectable amounts of both active components of Sulfatrim—sulfamethoxazole and trimethoprim—may remain present in the blood for up to 24 hours after the final dose has been administered.


Q: Is it safe to drink alcohol while completing a course of Sulfatrim?

A: Official labeling does not list a direct interaction between this drug and alcohol. However, alcohol consumption may potentially worsen certain gastrointestinal side effects already reported with the medication, such as nausea or vomiting.


Q: Does Sulfatrim affect the effectiveness of birth control pills?

A: Official regulatory documents note that there have been reports of reduced effectiveness of oral contraceptives when taken alongside antibiotics. The specific way in which antibiotics cause this effect is not clearly defined in the available regulatory literature.


Q: Are there any dietary restrictions, like avoiding high-potassium foods, while taking Sulfatrim?

A: The drug has been associated with an increase in potassium levels in the blood, a condition known as hyperkalemia. This reported fact is sometimes related to general precautions regarding the consumption of high-potassium foods.


Q: Does Sulfatrim interact with methotrexate or other chemotherapy agents?

A: Official labeling notes a pharmacokinetic interaction with methotrexate. The drug may increase the free plasma levels of methotrexate, which is relevant for patients who are taking other anti-folate medicines.


Q: Is it true that Sulfatrim may affect the function of the kidneys?

A: Regulatory documents note that caution is required when the drug is used in patients who have pre-existing impaired kidney function. The labeling also advises that adequate fluid intake should be maintained to help prevent the formation of crystals in the urine, known as crystalluria.


Q: Can the use of Sulfatrim lead to low levels of certain blood cells?

A: Official safety information lists hematologic side effects, which involve the blood cells. These side effects include the potential for low levels of certain blood cells, such as platelets (thrombocytopenia) or white blood cells (leukopenia).


Q: Is it normal to have a decreased appetite while taking Sulfatrim?

A: Yes, official product labeling includes a loss of appetite (anorexia) as one of the commonly reported side effects associated with the use of this medication.


Q: What official research evidence supports the use of Sulfatrim for its approved indications?

A: The efficacy of this drug for its approved antibacterial uses is confirmed by its inclusion on official public health lists. For example, the World Health Organization (WHO) includes the fixed-dose combination on its Model List of Essential Medicines, which confirms its necessary role and proven efficacy as a core therapeutic agent.

How should Sulfatrim be stored and disposed of?

Storage and Disposal of Sulfatrim

The official labeling for Sulfatrim (sulfamethoxazole and trimethoprim) mandates strict environmental conditions for stability and safety.

Storage Requirements

Item Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing and protect from light.
Container Must be dispensed in a tight, light-resistant container that is closed tightly.
Handling The oral suspension requires shaking well before each use.
Child Safety Keep out of reach of children.

Disposal Instructions

Outdated or unused medicine must not be kept. Regulatory guidelines require patients to ask a healthcare professional or pharmacist how to safely dispose of any medicine that is no longer needed, following recommended disposal protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulfatrim found in:

A-Z Index: